|
Post by mannmade on Sept 30, 2016 18:18:20 GMT -5
Slug I like your attitude and completely agree. See the quotes below my avatar that have been there since day 1.
|
|
|
Post by mannmade on Sept 29, 2016 21:40:24 GMT -5
Or the election results on election day/eve...
|
|
|
Post by mannmade on Sept 29, 2016 21:31:15 GMT -5
Glad I'm drinking tonight. 500 + tomorrow would be worth the hangover. 😉 And then some...
|
|
|
Post by mannmade on Sept 29, 2016 20:26:44 GMT -5
www.bloomberg.com/gadfly/articles/2016-09-29/novo-nordisk-job-cuts-diabetes-drug-price-war-casualtiesThe Diabetes Price War Claims Casualties By Max Nisen Max Nisen Sep 29, 2016 1:34 PM EDT MERCK & CO. INC.-1.39 AT CLOSING, SEP 29TH 61.91 USD CVS HEALTH CORP-0.63 AT CLOSING, SEP 29TH 89.55 USD Through no fault of their own, 1,000 people just became victims of a drug-price war mostly taking place on another continent. Danish pharma giant Novo Nordisk announced Thursday it is cutting 1,000 jobs (about half of them in Denmark), after last month slashing growth forecasts for 2016, citing lower U.S. prices for diabetes drugs. These will likely not be the last victims, either -- Novo and competitors such as Sanofi and Eli Lilly will likely have to keep tightening their belts as prices and profit margins fall.Diabetes is fertile ground for a drug-price fight. It's a $40 billion-plus market in the U.S., with many big firms looking to protect billion-dollar franchises. Each of the many medicines treating diabetes has multiple strong competitors. And all the customers want to pay less. Deflation Novo Nordisk's shares fell in August when it cut guidance due to U.S. diabetes-drug price pressure, and fell again on Sept. 29 as it announced 1000 job cuts Source: Bloomberg Diabetes is a chronic illness affecting millions of people -- a recipe for a lot of drug spending. Naturally, those who pay the drug bills -- insurers, pharmacy benefit managers (PBMs) and the U.S. government -- have an interest in keeping prices under control.And those payers have extra leverage against the pharma companies because of the sheer number of drugs on the market. In August, pharmacy benefit manager Express Scripts said it would decline next year to pay for several Novo Nordisk drugs -- which accounted for more than $7 billion in sales last year -- in favor of medicines from Eli Lilly and others. Novo Nordisk's competitors probably offered substantial discounts to get on the PBM's favored-drug list.ESTIMATED SIZE OF U.S. DIABETES-DRUG MARKET$40 Billion In Annual SalesCVS Health, meanwhile, said it will exclude Sanofi's long-acting insulin drugs Lantus and Toujeo (expected to combine for $6.8 billion in sales this year) next year in favor of Eli Lilly's similar drug, Basaglar, which rolls out in mid-December. UnitedHealth, a large health insurer that also has a large PBM segment, revealed it was doing the same.As new drugs and drug combinations hit the market and PBMs aggressively curate their favored drug lists, drugmakers are forced to continually raise the rebates, or discounts, they make to payers to stay competitive.For example, the implied rebate -- the percentage of gross drug sales given away in rebates and other discounts -- Sanofi gives for its drug Lantus has grown from around 10 percent in 2009 to nearly 60 percent last quarter, according to Bloomberg Intelligence. The discounting could get even more severe when Eli Lilly's rival drug Basaglar hits the U.S. market. State of Rebate In an increasingly competitive market, drugmakers with long-acting insulins have had to offer bigger and bigger rebates to payers Source: Bloomberg Intelligence The implied rebate is the difference between a drug's gross sales and what's left (net sales) after various rebates and discounts to private payers and the government. This is happening to many diabetes drugs. Eli Lilly and Novo Nordisk's short-acting insulins have implied rebates of about 70 percent, according to BI. Newer diabetes drugs in different classes, such as Eli Lilly's Trulicity, Merck's Januvia, and Novo's Victoza, also have large and rising rebates. Such price competition does not tend to suddenly reverse. It's actually more likely to increase -- agreements between payers and drugmakers get renegotiated every year, and PBMs have gotten more savvy and aggressive about playing companies against each other to get the biggest possible discounts, especially in large drug classes. For an example of the kind of impact this has on revenue, consider Sanofi's Lantus, the biggest-selling diabetes drug. Since 2014, Wall Street's consensus forecast for the drug's 2017 sales has fallen from $7.1 billion to $5.1 billion. Lantus is expected to fall below $4 billion in sales by 2019. Those 1,000 job cuts will likely not be the last.This column does not necessarily reflect the opinion of Bloomberg LP and its owners.To contact the author of this story: Max Nisen in New York at mnisen@bloomberg.netTo contact the editor responsible for this story: Mark Gongloff at mgongloff1@bloomberg.net
|
|
|
Post by mannmade on Sept 29, 2016 19:32:22 GMT -5
Awesome 500 um sorry guys but don't we need like 10000 plus a week to be profitable or wait was it 20000. Well maybe mannkind 3.0 can get it done. You must be on the wrong board? Read my post above or try some DD before you talk trash... (To be clear... Nimrod this was meant for your post above...)
|
|
|
Post by mannmade on Sept 29, 2016 19:26:53 GMT -5
Liane I am surprised actually coming from you... AS you are generally one of the most decisive and firm posters on the board...
|
|
|
Post by mannmade on Sept 29, 2016 19:17:44 GMT -5
Actually it's more like 5,000 or so as I understand it... And that's a number I can live with in October! Or put another way... Think about this, Mnkd would be at 10% toward break even by October. That's a big step at this time when looking at it from this POV imo. And that would be with a trend of continued growth... By March we could be at 40%, etc... All of which starts to become a more compelling story to investors... and WS.
|
|
|
Post by mannmade on Sept 29, 2016 19:13:39 GMT -5
If Only BP understood AFREZZA they would be knocking down Matt's door... With the new emphasis on the digital/information component as part of the healthcare process with both providers and insurance... AFREZZA's time is just about here. imho... abcnews.go.com/Business/wireStory/danish-drug-maker-novo-nordisk-lay-1000-42439590Danish Drug Maker Novo Nordisk to Lay off 1,000 Employees By THE ASSOCIATED PRESS COPENHAGEN, Denmark — Sep 29, 2016, 4:15 AM ET SHARE Email Danish drug maker Novo Nordisk says it plans to lay off some 1,000 employees globally to reduce operating costs because of "a challenging competitive environment, especially in its large U.S. market." One of the world's leading makers of diabetes medicines says half the job cuts are expected to be in Denmark. Copenhagen-based Novo Nordisk said Thursday the layoffs will affect its research and development departments, headquarters staff functions and global commercial organization. Group CEO Lars Rebien Soerensen said the layoffs are needed "for us to have a sustainable balance between income and costs," adding the company has "to prioritize investments." Novo Nordisk currently employs some 42,300 people in 75 countries and markets its products in more than 180 countries
|
|
|
Post by mannmade on Sept 29, 2016 8:30:33 GMT -5
It was a local Fox station and no not yet according to Laura's last tweet.
|
|
|
Post by mannmade on Sept 29, 2016 8:25:39 GMT -5
Not my areas but thought Symphony and IMS data were fairly current to the week prior. What is is his explanation about the veracity of their data which is estimated but supposed to be statistically correct within acceptable margins?
|
|
|
Post by mannmade on Sept 29, 2016 8:20:54 GMT -5
I am not sure that Onduo is the plan. Remember Sanofi is a partner and Brandecourt still runs Sanofi. Why would they drop it only to see it succeed with their partnership in Onduo.
|
|
|
Post by mannmade on Sept 28, 2016 22:20:04 GMT -5
What about MannKind Cares?
|
|
|
Post by mannmade on Sept 28, 2016 22:18:47 GMT -5
I spoke with Stefan a few times while he was at Sanofi and he told me more than once he thought AFREZZA delivered amazing results.
|
|
|
Post by mannmade on Sept 28, 2016 20:21:44 GMT -5
The below two paragraphs are pulled directly from the article at the above link... Tell me AFREZZA would not be better in most cases for the reasons I have previously stated...
"... Before going into the study my A1C was 7.6%. After the first six months, I came out with a 6.5%. It’s the device that is really being studied, not me. But learning about the technology and how it works allowed me to manage a lot better. This was a big eye-opener in taking better care of myself!
Any other surprises you’ve found with this technology?
One thing that I’ve noticed that many people like to refer to this as an 'artificial pancreas,' as if it were fully automated. It really isn’t, in my opinion. It provides you a lot of the benefits of continuous micro-boluses, but you still have to manage your diabetes on a daily basis in order for the device to work as it needs to. You’re still thinking about diabetes just as much -- at least that’s what I have found..."
Now AFREZZA:
1. AFREZZA is getting PWD as low as 4.8 and generally within mid 5's to low 6's for those that learn how to tritarate properly. (His is a 6.2 although may be better since article) 2. No carb counting 3. As Gus B and many others say, they live like they don't have diabetes anymore... (He is still thinking about it all day)
There are more comparisons to be made but for not I think I have made my point... Very disturbing that such a great drug is virtually ignored and a new piece of technology that is admittedly imperfect is getting such attention and phase...
|
|
|
Post by mannmade on Sept 28, 2016 20:07:54 GMT -5
Exactly my point... Why count carbs, why take a prandial or bolus at meal time? Why bother replacing a pump with another pump? Why not just use a cgm + basal + AFREZZA to get similar results? For C sake, they used AFREZZA in the trials...
|
|